GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » EV-to-EBIT

IsoPlexis (IsoPlexis) EV-to-EBIT : -0.44 (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IsoPlexis's Enterprise Value is $44.50 Mil. IsoPlexis's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-100.65 Mil. Therefore, IsoPlexis's EV-to-EBIT for today is -0.44.

The historical rank and industry rank for IsoPlexis's EV-to-EBIT or its related term are showing as below:

ISO' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.98   Med: -0.72   Max: -0.23
Current: -0.44

During the past 4 years, the highest EV-to-EBIT of IsoPlexis was -0.23. The lowest was -3.98. And the median was -0.72.

ISO's EV-to-EBIT is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 20.475 vs ISO: -0.44

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IsoPlexis's Enterprise Value for the quarter that ended in Dec. 2022 was $75.70 Mil. IsoPlexis's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-100.65 Mil. IsoPlexis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -132.96%.


IsoPlexis EV-to-EBIT Historical Data

The historical data trend for IsoPlexis's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis EV-to-EBIT Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
- - -3.38 -0.75

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.38 -0.89 -0.68 -0.71 -0.75

Competitive Comparison of IsoPlexis's EV-to-EBIT

For the Medical Devices subindustry, IsoPlexis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IsoPlexis's EV-to-EBIT falls into.



IsoPlexis EV-to-EBIT Calculation

IsoPlexis's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=44.497/-100.654
=-0.44

IsoPlexis's current Enterprise Value is $44.50 Mil.
IsoPlexis's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IsoPlexis  (NAS:ISO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IsoPlexis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 ) =EBIT / Enterprise Value (Q: Dec. 2022 )
=-100.654/75.70336
=-132.96 %

IsoPlexis's Enterprise Value for the quarter that ended in Dec. 2022 was $75.70 Mil.
IsoPlexis's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IsoPlexis EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of IsoPlexis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003